SCHEMBL446204

SCHEMBL446204

O=C(OCC(O)CO)c1ccccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 7/20 0.63
ADRB1 P08588 7/20 0.63
ADRB3 P13945 7/20 0.63
TDP1 Q9NUW8 2/20 0.57
LMNA P02545 2/20 0.54
ALDH1A1 P00352 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TSHR P16473 2/20 0.50
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HSD17B10 Q99714 3/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 1/20 0.46
CYP3A4 P08684 2/20 0.45
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MLNR O43193 1/20 0.45
ABCB11 O95342 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29613210 1.00 ADRB2 (0.63) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL17629572 1.00 ADRB2 (0.63) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL17629569 1.00 ADRB2 (0.63) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL12083435 0.91 ADRB2 (0.68) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL120454 0.90 ALDH1A1 (0.61) ADRB2ADRB1ADRB3ALDH1A1NPC1
SCHEMBL1031052 0.86 ADRB2 (0.53) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL24292233 0.85 ADRB2 (0.66) ADRB2ADRB1ADRB3TDP1LMNA
SCHEMBL16088412 0.85 ADRB2 (0.66) ADRB2ADRB1ADRB3TDP1LMNA
Glycerin SCHEMBL22574599 0.84 TDP1 (0.63) ADRB2ADRB1ADRB3TDP1LMNA
Ethyl Salicylate SCHEMBL27636321 0.84 TSHR (0.61) ADRB2ADRB1ADRB3TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115644177-B Neutral peracetic acid disinfectant and preparation method thereof 利康医药科技江苏有限公司 2024-03-15 CN claimed
CN-115644177-A Neutral peroxyacetic acid disinfectant and preparation method thereof 利康医药科技江苏有限公司 2023-01-31 CN claimed
EP-3197460-B1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES GREENPHARMA SAS (FR) 2022-04-20 EP claimed
CN-110746750-B Heat-insulating anti-ultraviolet glass film and preparation method thereof 湖南泉想湖智能科技有限公司 2021-12-17 CN claimed
CN-110746750-A Heat-insulating anti-ultraviolet glass film and preparation method thereof 宁波泰意德过滤技术有限公司 2020-02-04 CN claimed
US-20170281653-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES GREENPHARMA SAS (FR) 2017-10-05 US claimed
EP-3197460-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES Greenpharma (FR) 2017-08-02 EP claimed
WO-2016046456-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES GREENPHARMA (FR) 2016-03-31 WO claimed
CN-101448482-B Glyceryl and glycol acid compounds MARY KAY INC 2013-10-09 CN claimed
US-7932417-B2 Glyceryl and glycol acid compounds MARY KAY INC. (US) 2011-04-26 US claimed
CN-101448482-A Glyceryl and glycol acid compounds MARY KAY INC (US) 2009-06-03 CN claimed
EP-2026753-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS Mary Kay, Inc. (US) 2009-02-25 EP claimed
WO-2007137128-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS MARY KAY INC. (US) 2007-11-29 WO claimed
US-20070269391-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS MARY KAY, INC. (US) 2007-11-22 US claimed
US-4016264-A Wart treatment with phosphonoacetic acid or derivatives thereof THE UNIVERSITY OF UTAH (US) 1977-04-05 US claimed
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents COLABS INT'L CORP. (US) 2024-03-28 US disclosed
CN-115644177-B Neutral peracetic acid disinfectant and preparation method thereof 利康医药科技江苏有限公司 2024-03-15 CN disclosed
EP-0698393-A1 SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME Hisamitsu Pharmaceutical Co., Inc. (JP) 1996-02-28 EP disclosed
US-4886843-A CALCIUM HYDROXIDE CEMENT CHARACTERISTICS AND LIGHT CURE CHARACTERISTICS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-12-12 US disclosed
US-4229382-A STABILIZERS FOR POLYOLEFINS HOECHST AKTIENGESELLSCHAFT (DE) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070269391-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS GLA, GK, UNG ADRB2 3838/4885ADRB1 3694/4885ADRB3 3232/4885
US-20170281653-A1 DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOKINES CCL2, CCL11, CCL5 ADRB2 2720/4885ADRB1 2665/4885ADRB3 2814/4885
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents MSN, LIPE, CUTA ADRB2 4773/4885ADRB1 4731/4885ADRB3 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.